Haemonetics, a medical-device maker that focuses on markets including blood and plasma collection, is evolving to expand broadly with more diversification and greater sustainability over time, all with the view that good products win, CEO Chris Simon explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simon sits down with BI analyst Matt Henriksson to talk about Haemonetics and how its has built out its hospital franchise with M&A to include high-growth segments that diversifies the company beyond its traditional blood and plasma collection businesses. He also shares his views on how medtech companies need to have products with competitive advantages as the hospital environment rationalizes and whittles down the number of medtech suppliers they use.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.